ArticleAmerican journal of cancer research2025
Proteasomal deubiquitinating enzyme USP14/UCHL5 inhibitor bAP15 suppresses endoplasmic reticulum stress-mediated apoptosis and tumor growth in human chondrosarcoma.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chondrosarcoma is a malignant bone tumor with limited systemic options. Here, using the small-molecule probe bAP15 to inhibit proteasome-associated deubiquitinating enzymes (DUBs) USP14 and UCHL5, we evaluated the therapeutic concept of DUB inhibition in human chondrosarcoma. Immunohistochemistry showed higher USP14/UCHL5 expression in chondrosarcoma than in normal cartilage controls. In vitro, bAP15 increased Annexin V/PI-positive apoptosis and cleavage of caspase-3/PARP. Under our experimental conditions (low sub-micromolar exposure, 24-48 h), bAP15 led to a predominant accumulation of cells in G1, accompanied by p21 upregulation and reduced PCNA and phospho-histone H3. bAP15 was associated with lower phosphorylation of AKT/ERK and with the induction of ER-stress markers (GRP78, CHOP, IRE1α, caspase-4). In vivo, bAP15 suppressed xenograft growth. Collectively, these data support proteasome-associated DUB inhibition as a potential strategy in chondrosarcoma, with bAP15 serving as a chemical tool to probe this target class.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.